Evommune (NYSE:EVMN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Evommune (NYSE:EVMN) from a sell rating to a hold rating in a report issued on Sunday.

Several other analysts have also commented on EVMN. William Blair initiated coverage on Evommune in a report on Monday, December 1st. They issued an “outperform” rating on the stock. Cantor Fitzgerald started coverage on Evommune in a research report on Monday, December 1st. They set an “overweight” rating on the stock. Evercore ISI began coverage on shares of Evommune in a research note on Monday, December 1st. They issued an “outperform” rating and a $40.00 price target on the stock. Leerink Partners assumed coverage on shares of Evommune in a research report on Monday, December 1st. They set an “outperform” rating and a $42.00 price objective for the company. Finally, Morgan Stanley began coverage on shares of Evommune in a report on Monday, December 1st. They set an “overweight” rating and a $36.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Evommune presently has a consensus rating of “Buy” and an average target price of $39.33.

Evommune Price Performance

EVMN opened at $15.90 on Friday. Evommune has a fifty-two week low of $15.78 and a fifty-two week high of $24.03.

Evommune (NYSE:EVMN) last posted its earnings results on Thursday, December 11th. The company reported ($8.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.58) by ($1.49). The firm had revenue of $10.00 million for the quarter, compared to analyst estimates of $10.00 million.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.